The Patent III panel discussion from the Supreme Court IP Review (SCIPR), September 25, 2015, at Chicago-Kent College of Law focused on the case Kimble v. Marvel Enterprises, Inc. (declining to overrule Brulotte v. Thys Co., which held that a patentee\u27s use of a royalty agreement that projects beyond the expiration date of the patent is unlawful per se.)Moderator: David Clough, Morgan, Lewis & Bockius LLPPanelists: Thomas Saunders, WilmerHale, counsel for Marvel; David Applegate, Williams Montgomery & John, counsel for IPLAC as amicus curiae in support of neither party; Fiona Schaeffer, Milbank, Tweed, Hadley & McCloy LLP, counsel for the Association of the Bar of the City of New York as amicus curiae in support of neither party. Runtim...
The Patent II panel discussion from the Supreme Court IP Review (SCIPR) focused on the case Teva Pha...
In Kimble v. Marvel Enterprises, citing stare decisis, the Court held that a patent holder cannot ch...
Panelists and moderator at the Patent II Panel discuss Teva Pharmaceuticals v. Sandoz during the six...
The Patent III panel discussion from the Supreme Court IP Review (SCIPR), September 25, 2015, at Chi...
Panelists and moderator at the Patent III Panel discuss Kimble v. Marvel Enterprises, Inc. during th...
The Patent III panel discussion from the Supreme Court IP Review (SCIPR) focused on the case Kimble ...
The Patent I panel discussion from the Supreme Court IP Review (SCIPR), September 25, 2015, at Chica...
On March 31, 2015, the Supreme Court heard oral argument for two cases: Commil USA, LLC v. Cisco Sys...
Panelists and moderator at Patent I Panel discuss Commil USA v. Cisco during the sixth annual Suprem...
Moderator: Scott Burow, Attorney, Banner & Witcoff Ltd. The panel discusses the Supreme Court case B...
A clause in a patent license agreement which requires the licensee to continuously render royalty pa...
The Patent I panel discussion from the Supreme Court IP Review (SCIPR) focused on the case Commil US...
Professor Greg Dolin of the University of Baltimore School of Law discusses the dispute in Kimble v....
Moderator and panel members discuss Limelight Networks v. Akamai Technologies and Medtronic v. Mirow...
This is a brief of 72 IP professors opposing the claim in Oil States that the IPR procedure is uncon...
The Patent II panel discussion from the Supreme Court IP Review (SCIPR) focused on the case Teva Pha...
In Kimble v. Marvel Enterprises, citing stare decisis, the Court held that a patent holder cannot ch...
Panelists and moderator at the Patent II Panel discuss Teva Pharmaceuticals v. Sandoz during the six...
The Patent III panel discussion from the Supreme Court IP Review (SCIPR), September 25, 2015, at Chi...
Panelists and moderator at the Patent III Panel discuss Kimble v. Marvel Enterprises, Inc. during th...
The Patent III panel discussion from the Supreme Court IP Review (SCIPR) focused on the case Kimble ...
The Patent I panel discussion from the Supreme Court IP Review (SCIPR), September 25, 2015, at Chica...
On March 31, 2015, the Supreme Court heard oral argument for two cases: Commil USA, LLC v. Cisco Sys...
Panelists and moderator at Patent I Panel discuss Commil USA v. Cisco during the sixth annual Suprem...
Moderator: Scott Burow, Attorney, Banner & Witcoff Ltd. The panel discusses the Supreme Court case B...
A clause in a patent license agreement which requires the licensee to continuously render royalty pa...
The Patent I panel discussion from the Supreme Court IP Review (SCIPR) focused on the case Commil US...
Professor Greg Dolin of the University of Baltimore School of Law discusses the dispute in Kimble v....
Moderator and panel members discuss Limelight Networks v. Akamai Technologies and Medtronic v. Mirow...
This is a brief of 72 IP professors opposing the claim in Oil States that the IPR procedure is uncon...
The Patent II panel discussion from the Supreme Court IP Review (SCIPR) focused on the case Teva Pha...
In Kimble v. Marvel Enterprises, citing stare decisis, the Court held that a patent holder cannot ch...
Panelists and moderator at the Patent II Panel discuss Teva Pharmaceuticals v. Sandoz during the six...